Apollo Hospitals Enterprise Ltd.
NSE: APOLLOHOSPApollo Hospitals Enterprise Ltd.: A 30-second snapshot
Apollo Hospitals trades at Rs 8,945, up 23.29% over the past year and 11.75% over three months, near its 52-week high (52-week drawdown of -1.16%) and above both its 50-day (Rs 8,682) and 200-day (Rs 7,787) moving averages. FY26 results showed revenue of Rs 25,228 crore (up 16%) and PAT of Rs 2,002 crore (up 33%), against a trailing PE of 66.22x (41.74x forward) and ROE of 21.5%. Mean analyst rating stands at 1.43 across 31 analysts (1-5 scale, lower = more constructive).
P/E
66.2
Forward P/E
41.7
ROE
+21.5%
Debt / Equity
85.15
Profit Margin
+7.7%
Div. Yield
+0.2%
5Y ROE > 15%
2/5
5Y FCF > 0
4/5
Quality
68/100
News
8 headlines · 5 positive · 0 negative
Apollo Hospitals Share Price: शानदार मुनाफे के बाद ₹9,050 के पार, निवेशकों को मिला डिविडेंड का तोहफा - Whalesbook
Whalesbook
Apollo Hospitals FY26 Revenue Up 16% to ₹25,228 Cr, PAT Surges 33% - Whalesbook
Whalesbook
Apollo Hospitals के शेयरधारकों के लिए अच्छी खबर! कंपनी ने घोषित किए शानदार नतीजे, ₹2002 करोड़ का मुनाफा - Whalesbook
Whalesbook
Apollo Hospitals: లాభాల్లో దూసుకుపోయిన అపోలో.. ₹25,228 కోట్లు ఆదాయం, ₹2,002 కోట్లు లాభం - Whalesbook
Whalesbook
అపోలో హాస్పిటల్స్ షేర్ ధర ₹9,050కి ర్యాలీ: FY26లో లాభాల జోరు! - Whalesbook
Whalesbook
Recent context
- ·FY26 results (early August 2026) showed revenue of Rs 25,228 crore, up 16%, and PAT of Rs 2,002 crore, up 33%, alongside a dividend announcement.
- ·Mean analyst rating of 1.43 across 31 analysts (1-5 scale, lower = more constructive).
- ·The stock touched near Rs 9,050 intraday around the results and now sits at Rs 8,945, just below its nearest resistance level of Rs 8,950.
Strengths
- +ROE of 21.5% ranks 1st of 6 tracked Pharma-sector peers, with earnings growth of 35.6% over five years.
- +FY26 revenue rose 16% to Rs 25,228 crore and PAT rose 33% to Rs 2,002 crore, cited across multiple news outlets.
- +Price trades above both the 50-DMA (Rs 8,682) and 200-DMA (Rs 7,787), up 23.29% over 12 months and within 1.16% of its 52-week high.
- +Tracked news flow over the period is entirely non-negative: 5 positive, 3 neutral, 0 negative of 8 items.
Weaknesses
- −Trailing PE of 66.22x (41.74x forward) ranks 4th of 6 in the sector peer set, and composite quality score of 44 ranks 3rd of 6, behind SUNPHARMA and DIVISLAB (57 each).
- −ROE exceeded 15% in only 2 of the tracked years despite a current reading of 21.5%, with a consistency score of 63.
- −Debt-to-equity of 0.85x is on a rising trend against a profit margin of 7.7%.
- −Recent positive news flow is concentrated in a single FY26 results release republished across multiple language editions, rather than five distinct catalysts.
Open questions
- ?Does the gap between a 1st-of-6 ROE ranking and a 3rd-of-6 composite quality-score ranking reflect factors beyond point-in-time profitability, and what are they?
- ?What is driving the rising debt-to-equity trend, and how does it relate to the company's capacity-expansion plans?
- ?How does the 41.74x forward PE compare with the 35.6% five-year earnings growth rate embedded in current estimates?
- ?With price near the top of its 12-month range and just below the Rs 8,950 resistance level, what would a shift in underlying volume or news flow look like?
Peer comparison: Pharma
Ranks 3 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd.You're viewing | 66.2 | +21.5% | 44 |
| Industry avg | across 5 peers | 52.2 | +11.6% | 37 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 38.6 | — | 57 |
| DIVISLAB | Divi's Laboratories Ltd. | 85.5 | — | 57 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.4 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.1 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 29.5 | +8.8% | 4 |
Technical state
Current price
₹8,945.00
SMA 50
₹8,682.20
SMA 200
₹7,786.60
RSI (14)
55.6 (neutral)
From 52w high
-1.2%
1Y return
+23.3%
3M return
+11.8%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumTrailing PE of 66.22x (forward 41.74x) ranks 4th of 6 in the tracked Pharma peer set - above CIPLA (35.09x), DRREDDY (29.50x) and SUNPHARMA (38.61x), below MAXHEALTH (72.44x) and DIVISLAB (85.47x). Composite quality score of 44 ranks 3rd of 6, behind SUNPHARMA and DIVISLAB (57 each).
- mediumROE has exceeded 15% in only 2 of the tracked years despite a current reading of 21.5%, with a consistency score of 63. Debt-to-equity of 0.85x is on a rising trend against a profit margin of 7.7%.
- low5 of 8 tracked news items are classified positive with 0 negative, but the positive items are dominated by a single FY26 results release (revenue of Rs 25,228 crore up 16%, PAT of Rs 2,002 crore up 33%) republished across multiple language editions rather than five distinct catalysts.
- lowThe tracked peer set for APOLLOHOSP mixes pure pharmaceutical manufacturers (CIPLA, DRREDDY, SUNPHARMA, DIVISLAB) with a single hospital operator (MAXHEALTH); priceChange1Y is unavailable (null) for all 5 listed peers, so relative price-performance ranking within the sector could not be computed.
Cross-section contradictions
- ROE of 21.5% ranks 1st of 6 in the tracked peer set, yet the composite quality score of 44 ranks only 3rd of 6 - behind SUNPHARMA (57) and DIVISLAB (57) - indicating the quality metric is not driven primarily by the point-in-time ROE figure.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 12 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 8 Aug 2026 · rotates through NIFTY 500 every ~5 days